Allogene Therapeutics Financial Statements (ALLO)
|
|
|
|
Report date
|
|
|
27.02.2020 |
25.02.2021 |
23.02.2022 |
28.02.2023 |
14.03.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
38.5 |
0.243 |
0.095 |
|
0.043 |
|
Operating Income, bln rub |
|
|
-202.0 |
-258.2 |
-255.8 |
-335.4 |
-327.7 |
|
-279.6 |
|
EBITDA, bln rub |
? |
|
-179.9 |
-250.8 |
-169.7 |
-335.4 |
-300.3 |
|
-269.0 |
|
Net profit, bln rub |
? |
|
-184.6 |
-233.5 |
-244.8 |
-329.8 |
-327.3 |
|
-283.4 |
|
|
OCF, bln rub |
? |
|
-137.4 |
-115.1 |
-184.8 |
-220.5 |
-237.7 |
|
-217.3 |
|
CAPEX, bln rub |
? |
|
50.8 |
66.0 |
21.4 |
5.19 |
1.52 |
|
0.618 |
|
FCF, bln rub |
? |
|
-188.1 |
-181.1 |
-206.3 |
-225.7 |
-239.2 |
|
-217.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
202.0 |
258.2 |
294.3 |
335.7 |
84.9 |
|
272.4 |
|
Cost of production, bln rub |
|
|
5.03 |
11.5 |
13.1 |
16.7 |
242.9 |
|
61.9 |
|
R&D, bln rub |
|
|
144.5 |
193.0 |
220.2 |
256.4 |
242.9 |
|
194.8 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
17.1 |
0.000 |
|
0.466 |
|
|
Assets, bln rub |
|
|
717.8 |
1 228 |
1 039 |
817.1 |
642.8 |
|
589.1 |
|
Net Assets, bln rub |
? |
|
629.0 |
1 080 |
916.4 |
665.9 |
512.2 |
|
463.7 |
|
Debt, bln rub |
|
|
51.3 |
53.8 |
69.9 |
95.1 |
95.1 |
|
85.1 |
|
Cash, bln rub |
|
|
588.9 |
1 032 |
809.5 |
576.5 |
448.7 |
|
291.6 |
|
Net debt, bln rub |
|
|
-537.5 |
-978.3 |
-739.6 |
-481.3 |
-353.6 |
|
-206.4 |
|
|
Ordinary share price, rub |
|
|
26.0 |
25.2 |
14.9 |
6.29 |
3.21 |
|
2.97 |
|
Number of ordinary shares, mln |
|
|
101.1 |
120.4 |
135.8 |
143.1 |
156.9 |
|
209.2 |
|
|
Market cap, bln rub |
|
|
2 626 |
3 038 |
2 026 |
900 |
504 |
|
621 |
|
EV, bln rub |
? |
|
2 088 |
2 060 |
1 287 |
419 |
150 |
|
415 |
|
Book value, bln rub |
|
|
629 |
1 080 |
916 |
666 |
512 |
|
464 |
|
|
EPS, rub |
? |
|
-1.83 |
-1.94 |
-1.80 |
-2.30 |
-2.09 |
|
-1.35 |
|
FCF/share, rub |
|
|
-1.86 |
-1.50 |
-1.52 |
-1.58 |
-1.52 |
|
-1.04 |
|
BV/share, rub |
|
|
6.22 |
8.97 |
6.75 |
4.65 |
3.26 |
|
2.22 |
|
|
EBITDA margin, % |
? |
|
|
|
-441.0% |
-138 045% |
-316 098% |
|
-625 519% |
|
Net margin, % |
? |
|
|
|
-636.1% |
-135 726% |
-344 489% |
|
-659 137% |
|
FCF yield, % |
? |
|
-7.17% |
-5.96% |
-10.2% |
-25.1% |
-47.5% |
|
-35.1% |
|
ROE, % |
? |
|
-29.3% |
-21.6% |
-26.7% |
-49.5% |
-63.9% |
|
-61.1% |
|
ROA, % |
? |
|
-25.7% |
-19.0% |
-23.6% |
-40.4% |
-50.9% |
|
-48.1% |
|
|
P/E |
? |
|
-14.2 |
-13.0 |
-8.28 |
-2.73 |
-1.54 |
|
-2.19 |
|
P/FCF |
|
|
-14.0 |
-16.8 |
-9.82 |
-3.99 |
-2.11 |
|
-2.85 |
|
P/S |
? |
|
|
|
52.6 |
3 705 |
5 303 |
|
14 449 |
|
P/BV |
? |
|
4.18 |
2.81 |
2.21 |
1.35 |
0.98 |
|
1.34 |
|
EV/EBITDA |
? |
|
-11.6 |
-8.21 |
-7.58 |
-1.25 |
-0.50 |
|
-1.54 |
|
Debt/EBITDA |
|
|
2.99 |
3.90 |
4.36 |
1.43 |
1.18 |
|
0.77 |
|
|
R&D/CAPEX, % |
|
|
284.6% |
292.6% |
1 027% |
4 939% |
16 023% |
|
31 519% |
|
|
CAPEX/Revenue, % |
|
|
|
|
55.7% |
2 136% |
1 596% |
|
1 437% |
|
| Allogene Therapeutics shareholders |
